insights_auto
Outlook: 59.1% bullish·13.6% bearish
Go to analysischevron_right
GENIL:IST
Gen Ilac ve Saglik Urnlr Snyi ve Tcrt AS
TRY 6.50
arrow_downward
-1.81%(-0.12) 1D
Sep 29, 6:10:00 PM GMT+3 · TRY
search
All symbols
No data
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GENIL...
Open
TRY 6.62
High
TRY 6.82
Low
TRY 6.30
Mkt. cap
29.25B
Avg. vol.
47.19M
Volume
33.73M
Dividend
0.52%
Quarterly dividend
TRY 0.01
Ex-dividend date
Nov 12, 2025
P/E ratio
25.08
52-wk high
TRY 14.93
52-wk low
TRY 6.07
EPS
TRY 0.26
Shares outstanding
4.50B
No. of employees
689
Open
TRY 6.62
High
TRY 6.82
Low
TRY 6.30
Mkt. cap
29.25B
Avg. vol.
47.19M
Volume
33.73M
Dividend
0.52%
Quarterly dividend
TRY 0.01
Ex-dividend date
Nov 12, 2025
P/E ratio
25.08
52-wk high
TRY 14.93
52-wk low
TRY 6.07
EPS
TRY 0.26
Shares outstanding
4.50B
No. of employees
689
News stories
From web sources and news partners
TipRanks
·
8 hours ago
Gen İlaç Launches Three-Year, TRY 1.5 Billion Share Buy-Back Program
TipRanks
·
16 hours ago
Gen İlaç Launches Three-Year, TRY 1.5 Billion Share Buy-Back
About Gen Ilac ve Saglik Urnlr Snyi ve Tcrt AS
Previous reportsAll values in TRY
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in TRY | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 5.35B | 4.82B | 7.09B | 6.97B |
Cost of goods sold | 4.32B | 3.75B | 5.00B | 5.48B |
Cost of revenue | 4.32B | 3.75B | 5.00B | 5.48B |
Research and development expenses | 580.70K | 21.03M | 23.90M | 51.05M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 501.22M | 843.92M | 806.92M | 664.31M |
Operating expense | 426.35M | 790.82M | 880.32M | 718.61M |
Total operating expenses | 4.75B | 4.54B | 5.88B | 6.20B |
Operating income | 605.72M | 283.17M | 1.20B | 765.26M |
Other non operating income | -7.60M | -170.09M | -298.92M | 61.07M |
EBT including unusual items | 341.19M | 545.00M | 555.09M | 307.89M |
EBT excluding unusual items | 337.85M | 525.72M | 757.78M | 281.24M |
Income tax expense | 127.68M | 396.92M | 154.40M | -180.82M |
Effective tax rate | 37.42% | 72.83% | 27.81% | -58.73% |
Other operating expenses | -75.45M | -74.13M | 49.51M | 3.25M |
Net income | 215.77M | 150.56M | 401.45M | 490.33M |
Net profit margin | 4.03% | 3.12% | 5.66% | 7.04% |
Earnings per share | - | - | - | - |
Interest and investment income | 36.19M | 685.62M | 94.64M | 76.42M |
Interest expense | -228.09M | -269.26M | -258.79M | -552.43M |
Net interest expenses | -191.90M | 416.36M | -164.15M | -476.01M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 759.45M | 436.90M | 1.34B | 779.78M |
Gain or loss from assets sale | -570.34K | -4.70M | -262.52K | -25.12M |